The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Registration for our Biopharmaceutical Informatics Symposium is open!

by

Biopharmaceutical informatics calls for the use of computational technologies such as AI/ML, digitalization, and molecular simulations to curate, analyze, visualize and interpret experimental data and provide data-informed inputs at every stage of biologic drug discovery and development projects. This interdisciplinary endeavor enables in-project as well as across project learnings from the laboratory results and also allows for disruptive innovations to accelerate biologic drug discovery. In recent years, biopharmaceutical informatics has emerged as a field of its own as the use of computation in biologic drug discovery and development has steadily increased, thereby, revolutionizing how we discover and develop biologic drugs.

Our virtual Biopharmaceutical Informatics Symposium, organized by Drs. Sandeep Kumar and Victor Greiff, will address questions about how we can bring novel biotherapeutic products to patients more often, faster and at affordable costs using biopharmaceutical informatics. Our expert speakers include Lucy Colwell (Google Research) Konrad Krawczyk (Natural Antibody), Peter Tessier (University of Michigan), and Charlotte Deane (University of Oxford). We will also have a panel discussion with the speakers and Ajay Royyuru (IBM), and Andrew E. Nixon (Boehringer Ingelheim Pharmaceutical Inc.).

Please join us on September 29, 2o22!
More information and the link to registration are here.

TECVAYLI® (teclistamab) approved in the European Union

by

On August 24, 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first approval worldwide for TECVAYLI® (teclistamab) by the European Commission, which granted conditional marketing authorization (CMA) of TECVAYLI® as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

Teclistamab (JNJ-64007957) is an IgG4l T-cell redirecting antibody derived from Ligand’s transgenic mouse (OmniAb) and Genmab’s DuoBody technology. The antibody selectively targets BCMA and CD3. Teclistamab was granted the European Medicines Agency’s PRIME designation for treatment of adult patients with relapsed or refractory MM who previously received ≥3 prior lines of therapy in 2021. Teclistamab had previously been granted Orphan Drug designations for MM in both the US and EU, and FDA granted Breakthrough Therapy designation to teclistamab for the treatment of relapsed or refractory MM.

The CMA was supported by positive results from the multicohort, open-label Phase 1/2 MajesTEC-1 study (NCT03145181 and NCT04557098), evaluating the safety and efficacy of teclistamab in adults with RRMM (n =165). In the MajesTEC-1 study, treatment with teclistamab resulted in deep and durable responses. The median duration of progression-free survival and the median duration of overall survival were 11.3 months (95 percent CI; range, 8.8–17.1) and 18.3 months (95 percent CI; range, 15.1–not estimable), respectively.

Janssen submitted a biologics license application to the US Food and Drug Administration seeking approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma in December 2021.

Data for all approved antibody therapeutics can be found here.

UK-based Senior Molecular Biologist position open

by

This senior level position will be held in the Centre for Cancer Immunology at Southampton General Hospital. This is a newly constructed, dedicated research building that is the result of a significant fund-raising campaign. It builds on a 40 year history of pioneering immunology and cancer research at Southampton, and represents the first dedicated cancer immunology centre in the UK. The activities in this centre span from pioneering discovery science to applied research and preclinical modelling and, crucially, onto first-in-human clinical trials and beyond. The centre houses world-class research facilities, including state-of-the-art scientific laboratories and a clinical trials unit.

The position is associated with the laboratory of Professors Ward and Ober. Their interdisciplinary research program is dedicated to the use of protein engineering to develop novel antibody-based therapeutics that in the past has led to several therapeutics that are approved for clinical use. The group is also actively involved in the development of advanced microscopy techniques for the evaluation of novel therapeutics in cellular environments. Their interdisciplinary research is funded by major grants from the Wellcome Trust, Cancer Research UK and support from collaborating biopharma companies.

More information on the role, responsibilities and requirements can be found here.

Application can be made online here.

The Huston Antibody Science Talent Award competition is open!

by

The James S. Huston Antibody Science Talent Award is sponsored by The Antibody Society to recognize and encourage upcoming scientists in the field of Antibody Engineering and Therapeutics. Early career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past ten (10) years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a lecture on their work, which will be made available on-line on The Antibody Society’s website, and to give a lecture at the Antibody Engineering & Therapeutics conference in December 2022.

The award includes: international recognition of the scientist’s accomplishments, a $1500 USD prize, and travel costs and registration fees to attend the annual Antibody Engineering & Therapeutics conference in San Diego, California.

The nomination process details are here. The deadline for submission is September 15, 2022.

The Society has selected mAbs as its Official Journal!

by

The Antibody Society is pleased to announce that it has partnered with Taylor & Francis, a leading research publisher, to make mAbs the Society’s Official Journal. mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.

Since 2009, mAbs has published high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:

  • Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific antibodies, and single-domain antibodies
  • Machine learning and artificial intelligence applications
  • Non-clinical studies of antibodies, such as mechanism of action studies, safety, and efficacy studies in animals
  • Manufacturing and formulation
  • Regulatory review of antibody therapeutics
  • Post-approval topics, such as markets

The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year. Articles in the current volume (14) can be found here.

Members of The Antibody Society receive a 10% discount on article publication charges using their member code.

We look forward to a productive partnership with Taylor & Francis.